| Title： | Expert consensus on economic evaluations alongside clinical trials in China |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Administration |
| Countries and regions： | China |
| Guidelines users： | Researchers who design and conduct clinical trials and pharmacoeconomic evaluations of clinical trials in China, and decision makers in relevant departments of health care and health insurance management. |
| Evidence classification method： | Because this consensus is not an evidence-based guideline based on systematic evaluation, it does not grade the quality of evidence and strength of recommendation. |
| Development unit： | Professional Committee of Pharmacoeconomics of Chinese Pharmaceutical Association |
| Registration time: | 2024-04-12 |
| Registration number： | PREPARE-2024CN528 |
| Purpose of the guideline: | It aims to develop a consensus guidance document for Chinese scholars and the pharmaceutical industry around the theme of how to load pharmacoeconomic evaluation in clinical trials from the perspective of China's healthcare system and decision-making environment. |
Latest registration
